Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: john.d who wrote (7795)	10/6/2001 9:23:44 PM
From: DaveAu	Respond to of 14101

Rebecca was asked about sales in Thailand at the last AGM. She didn't put a number on it (surprise) but seemed to indicate they were very low and also that few could afford it. My guess is that it is not marketed aggressively. As far as foreign sales, you have to remember that WF10 is delivered intravenously which means a hospital visit. If it were a pill, I could imagine foreigners loading up and taking it home but how many actually want to check into a hospital in Thailand. Desperate patients will always find there are many other experimental treatments that can be tried at home. Also remember that the reported WF10 trials have been tiny and they haven't resulted in any main stream media coverage. Oxo also sells a lower strength formula of WF10 as a wound healing treatment in a number of countries. I asked DMX what the revenues were (back in Peter Block days) and they wouldn't say (another surprise). I also asked if DMX would market it in Canada but Peter indicated that the product probably couldn't be approved in Canada or the U.S. without further trials so there were no plans to do this. Dave

To: john.d who wrote (7795)	10/6/2001 9:38:55 PM
From: Mark Bartlett	Respond to of 14101

John, I think Bluejay covered the points nicely -- I have nothing to add. MB